Stockreport
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors [MarketWatch]
Last acorda therapeutics, inc earnings: 2/14 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations: acorda.com/investors
PDF
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors Shares of biotech Acorda Therapeutics Inc. ACOR, +1.01% surged 20% in premarket trade Friday, after media reports that Biogen Inc. BIIB, -0.12% and others are eyeing the company as a possible takeover target. The speculation has been swirling for more than a week. On Thursday, the company offered preliminary guidance for 2017 sales of $542 million, an increase of approximately 10% from 2016. The FactSet consensus is for sales of $568 million. Chief Executive Ron Cohen said he expects 2018 to be a transformative year and for the company to achieve approval and launch its Inbrija investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking carbidopa/levodopa. Shares have gained 21% in the last 12 months, while the S&P 500 SPX, -0.16% has gained about 24%.
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | ACOR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
ACOR alerts
ACOR alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOR alerts
High impacting Acorda Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
ACOR
NEWS
NEWS
- Acorda Therapeutics Inc (NASDAQ: ACOR) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating.[MarketBeat]
- Acorda Therapeutics (ACOR) Q4 2018 Earnings Conference Call Transcript [The Motley Fool][The Motley Fool]
- Acorda Therapeutics Inc (NASDAQ: ACOR) had its "hold" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock.[MarketBeat]
- Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2018 Results - Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q4 2018 Results - Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- More
ACOR
SEC Filings
SEC Filings
- 2/14/19 - Form 8-K
- 2/14/19 - Form SC
- 2/14/19 - Form SC
- ACOR's page on the SEC website
- More